Key Challenges in KOL Engagement for Co-Commercialization Agreements

Co-commercialization agreements have become a common way for organizations to combine resources and extend market reach. A co-commercialization agreement is a partnership in which two or more organizations jointly develop, market, and distribute a healthcare product, sharing responsibilities and resources across the product lifecycle. A central part of this collaboration is engaging with Key Opinion Leaders (KOLs), the respected experts whose insight and credibility shape how a therapy is understood and adopted. For Medical Affairs teams, that engagement is essential, and it carries a distinct set of challenges when more than one organization is involved.

Key Takeaways

• Co-commercialization multiplies stakeholders, not just resources. Every partner organization brings its own view of who counts as a valuable KOL, which strategy to follow, and how to share what is learned.
• Selection and prioritization is usually the first friction point. Aligning multiple organizations on a single, mutually agreed KOL list requires shared selection parameters before outreach begins.
• Strategy misalignment is costly to fix after the fact. Time spent aligning on communication channels, interaction frequency, and compliance viewpoints upfront is cheaper than correcting a fragmented approach later.
• Coordination protects the KOL relationship. Without a shared engagement calendar, KOLs can be overburdened or given conflicting messages from different partners.
• Insight-sharing is often the hardest technical problem. Differing CRM systems, data protocols, and confidentiality requirements can trap valuable KOL feedback inside a single partner's systems.

This article covers the four challenges Medical Affairs teams most often encounter in KOL engagement within co-commercialization agreements.

1. Selection and Prioritization of KOLs

The work begins with identifying and prioritizing the KOLs who provide the most value to the partnership. Each organization involved may have its own view of which KOLs are most influential and relevant to the product or therapy area under consideration. Finding common ground across those views is often the first major hurdle. The collaborating Medical Affairs teams need to collectively prioritize KOL initiatives and activities aligned to the commercialization continuum. Through that process, they can establish a mutually agreed KOL list that aligns with their joint medical objectives.

For a closer look at building a shared, data-driven KOL selection process, see A Roadmap to Success: KOL Selection and Prioritization in Co-Commercialization Agreements.

2. Aligning on Engagement Strategy

Different organizations have distinct strategies for KOL engagement, involving varied communication channels, interaction frequencies, engagement types, and compliance viewpoints. Aligning these disparate strategies into a coherent, consistent approach is a significant challenge. Correcting a misalignment after engagement is underway is harder still; the impact can linger and require substantial time and resources to rectify, compared with investing the time in strategic alignment at the outset. The parties involved need clear lines of communication, mutual understanding, and a willingness to compromise. The goal is a strategy that reflects the interests and values of all parties and supports consistent engagement with the KOLs.

For a deeper look at reconciling partner strategies, see Aligning KOL Engagement Strategies in Co-Commercialization Agreements.

3. Coordinating Engagement Activity

When multiple organizations engage the same KOLs, the risk of overlapping or conflicting activity becomes substantial. This calls for careful coordination to avoid overburdening KOLs or delivering mixed messages. A well-coordinated approach respects the KOLs' time and commitments while ensuring that all parties receive the interactions and insights they need. Collaborative planning, together with open and ongoing communication, is central to success here.

4. Sharing KOL Insights

The insights and feedback gathered from KOLs are valuable, and sharing them between companies can be difficult. Confidentiality requirements, differing data systems, and separate company policies can all obstruct smooth information sharing. Establishing clear guidelines and processes allows partners to share insights appropriately, efficiently, and in a way that remains consistent with industry compliance standards such as the PhRMA Code.

For strategies on integrating systems and standardizing data protocols across partners, see Pharmaceutical Commercial Strategy: Sharing KOL Insights in Co-Commercialization Agreements.

KOL engagement across a co-commercialization partnership is demanding work. It calls for strategic planning, clear communication, and flexibility. By recognizing and addressing these four challenges directly, Medical Affairs teams can get more from their co-commercialization efforts while maintaining strong, compliant relationships with their KOLs.

Medical Affairs teams evaluating how to structure KOL engagement across a co-commercialization partnership can also review AP's Medical Affairs Consulting services for support building the underlying process and infrastructure.

Curious how this applies to your organization? Let's talk.

Further Reading:

• KOL Selection and Prioritization in Co-Commercialization Agreements → https://www.accelerationpoint.com/resources/kol-selection-and-prioritization/
• Aligning KOL Engagement Strategies in Co-Commercialization Agreements → https://www.accelerationpoint.com/resources/aligning-kol-engagement-strategies/
• Sharing KOL Insights in Co-Commercialization Agreements → https://www.accelerationpoint.com/resources/sharing-kol-insights/
• KOL Engagement: Components of a Successful Strategy → https://www.accelerationpoint.com/resources/kol-engagement-components-of-a-successful-plan/